ASH News Daily - Saturday, December 10, 2011 - (Page B-33)

Saturday, December 10, 2011 ASH NewS DAily Page B–33 ® FocuS on earlycareer hematologiStS Trainees: We Want To Hear From You In keeping with ASH’s commitment to providing trainees with products and services to ensure their success in the field of hematology, the ASH Trainee Council is currently soliciting feedback on how ASH can better meet trainee needs. To submit feedback on existing ASH trainee programs, please complete the Feedback Form at www.hematology. org/training. All comments will receive a response from a member of the ASH Trainee Council. Trainees «« From Page B-30 Trainee Simultaneous Didactic Sessions During lunch on Sunday and Monday, ASH will provide two simultaneous didactic sessions designed to offer trainees an overview of timely and relevant career-oriented issues. A boxed lunch will be provided. Space is available on a first-come, first-served basis. As seating is limited, attendees are strongly encouraged to arrive early. No addiJOB#: 10561 tional persons will be allowed in the PROOF#: 1 CLIENT: Alexion rooms once these sessions are filled. Dr. Chaitra Ujjani, Georgetown University, asks a question of Dr. Martin B:8.75 in Tallman, New York, NY, after his presentation on “Funding and Career T:7.5 in Development for the Clinician and Clinician Investigator,” during Trainee Day S:6.75 in at last year’s ASH annual meeting in Orlando. n xio 29 Ale 8 it oth Vis bo at Sunday, December 11 11:15 a.m. - 12:15 p.m. Workforce Issues in Hematology: Where the Jobs Are San Diego Convention Center, Room 31 Linda Burns, MD, University of Minnesota Ethics Misconduct and Research Integrity San Diego Convention Center, Room 33 Nancy Kernan, MD, Memorial Sloan-Kettering Cancer Center DESC: Disease Concept Jrnl Ad Color: 4C AD: NT TRAFFIC: CR OPERATOR: zv GALLEY#: 1 DATE: 10/19/11 - 7:53 PM CREATED: 7/22/11 - 5:38 PM FONTS: Trade Gothic LT Std Bold Condensed No. 20, Trade Gothic LT Std Bold No. 2, Trade Gothic LT Std Regular, Trade Gothic LT Std Condensed No. 18, Trade Gothic LT Std Condensed No. 18 Oblique IMAGES: 10561C_journalAD_fn.tif, Alexion_KO.eps COLORS: C=0 M=100 Y=75 K=5 NOTES: DOC PATH: Macintosh HD:Users:vazz:Desktop:10/19:ALX_ SLR_Q10561C_JA_D01:ALX_SLR_ Q10561C_JA_D01.indd DOC SIZE: 10.75” X 13.25” PRINT SCALE: 100% Monday, December 12 12:15 - 1:15 p.m. Drug Development – Bench to Bedside and Beyond San Diego Convention Center, Room 31 John Leonard, MD, Cornell University How to Publish a Manuscript in a Peer-Reviewed Journal San Diego Convention Center, Room 33 Cindy Dunbar, MD, Editor inChief, Blood 20658a C M Y K Cosmos Communications 718.482.1800 CATaHUSTROPHIC In atypical Hemolytic Uremic Syndrome (aHUS), chronic uncontrolled complement activation causes systemic thrombotic microangiopathy (TMA), which can result in sudden and progressive vital organ failure and premature death1-5 Chronic uncontrolled complement activation causes the continuous activation of platelets and endothelial cells, leading to systemic TMA.3,6 Systemic, complement-mediated TMA can lead to sudden, fatal complications and progressive failure of vital organs, including the kidneys, heart, and brain.1-4,7 aHUS is a devastating and life-threatening disease of chronic uncontrolled complement activation.1,2,5 Recycle Abstract and Program Books If you will be disposing of your Abstract Book, Program Book, or any other paper materials, please be sure to recycle them. Throughout the convention center there are clearly marked, bright blue recycling bins for your convenience. Thank you for helping ASH lessen its carbon footprint. 10.19.11 133 1 ej 2 Q1 Q2 To learn more about aHUS, please visit booth 829 and www.aHUSsource.com References: 1. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008;23:1957-1972. 2. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859. 3. Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol. 2008;143:336-348. 4. Sallée M, Daniel L, Piercecchi MD, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant. 2010;25:2028-2032. 5. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36:673-681. 6. Ståhl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood. 2008;111:53075315. 7. Neuhaus TJ, Calonder S, Leumann EP. Heterogeneity of atypical haemolytic uraemic syndromes. Arch Dis Child. 1997;76:518-521. Copyright © 2011, Alexion Pharmaceuticals, Inc. All rights reserved. SOL 1172A  http://www.hematology.org/training http://www.hematology.org/training

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com